Wall Street has been kinder to InterMune, which reported pivotal data on pirfenidone, a potential blockbuster drug for idiopathic pulmonary fibrosis, a disease with no real current treatment. The data was mixed, but investors are counting on the desperate need for a new drug to sway regulators. -KT

Meanwhile, GlaxoSmithKline made headlines around the world with its decision to lay off 6,000 to 10,000--a tough blow at a time when even departing Pfizer execs are seeing their severance packages significantly reduced (but still pretty darn lavish compared to us mere mortals). -KT

Meanwhile, there was actually an IPO in the last month! Mead Johnson Nutrition isn't exactly an unknown entity; it's a unit of Bristol Myers-Squibb widely known for its Enfamil infant formula, and BMS is holding onto 85% of the company. Still, it priced at the top end of its expected range and has gone up since then. That's something, isn't it? -KT

BioSpace, Inc.
Ramshorn Executive Centre
2399 Highway 34, Building A-5
Manasquan, New Jersey 08736-1528 U.S.A.
Phone: 732-528-3688
Fax: 732-528-3668

BioSpace, Inc.
90 New Montgomery Street, Suite 414
San Francisco, California 94105 U.S.A.
Phone: 877-277-7585
Fax: 415-576-9217